Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshinobu Yoshimura is active.

Publication


Featured researches published by Yoshinobu Yoshimura.


Journal of Chromatography B: Biomedical Sciences and Applications | 1993

Automated high-performance liquid chromatographic determination of hydroxylysylpyridinoline and lysylpyridinoline in urine using a column-switching method

Yoshinobu Yoshimura; Koji Ohnishi; Misako Hamamura; Tsuneo Oda; Takashi Sohda

An on-line urine clean-up system was developed for the simultaneous determination of free and total pyridinoline, hydroxylysyl-pyridinoline (HP) and lysylpyridinoline (LP) by high-performance liquid chromatography (HPLC) using a column-switching technique. The method is based on a combination of gel permeation chromatography (GPC) and ion-pair reversed-phase HPLC. In the GPC column, pyridinoline is preseparated from endogenous urinary substances with 0.03 M heptafluorobutyric acid (HFBA) as the mobile phase. After column switching, the eluate fraction containing pyridinoline is further separated by ion-pair chromatography using an octadecylsilica (ODS) column with 0.03 M HFBA-acetonitrile (81:19) as the mobile phase. The detection limits were 36 and 44 pmol/ml for free and total HP, respectively, and 44 pmol/ml for both free and total LP at a signal-to-noise ratio of 3. The coefficients of variation for free and total pyridinoline were 1.5 and 3.5%, respectively. The determination of one sample including the clean-up is completed within 25 min. This system is precise and is useful for the determination of pyridinoline in large amounts of urine. The usefulness of pyridinoline as a biomedical marker for bone resorption was also examined.


International Journal of Pharmaceutics | 1985

Synthesis and relation between physicochemical properties and oral absorption of 7-O-acylmandelamido-3-methyl-3-cephem-4-carboxylic acids☆

Yoshinobu Yoshimura; Naoru Hamaguchi; Nobuharu Kakeya; Takatsuka Yashiki

O-Acylates (IV) of 7-d-mandelamido-3-methyl-3-cephem-4-carboxylic acid (I) were prepared and their physicochemical properties and oral absorption in mice were measured to search for an orally active cephalosporin having a 7-acyl group other than phenylglycine analogs. The pKa and log P values of IB were 2.8 and 1.02–3.54, respectively, and IV were hydrolyzed to the parent drug (I) in a homogenate of mouse small intestine. The esters, IVb (propionate), IVc (n-butyrate), IVd (i-butyrate), and IVe (n-valerate) produced higher plasma levels of I and improved relative bioavailability (BA) than those observed after oral dosing with I. Among the esters, IVe showed the highest BA, 40.3%. Good correlations between log P and log BA and between log P and peak plasma level (log Cmax) were observed. The esters resulting in good BA have log P values similar to those of orally active penicillins having an acyl group other than phenylglycine analogs, e.g. propicillin (PP-PC) and phenethicillin (PE-PC). The present study indicates that an ester prodrug of the parenteral cephalosporin having a 7-acyl group other than phenylglycine analog can be absorbed effectively through the gastrointestinal tract when log P and the pKa values are in a selected range.


Journal of Chromatography B: Biomedical Sciences and Applications | 1999

Application of liquid chromatography-turbo ion spray tandem mass spectrometry for quantitative analysis of a potent motilin receptor agonist, EM574, and its metabolites in human plasma.

Takahiro Kondo; Nobuhito Dote; Toshiaki Hagimoto; Yoshinobu Yoshimura

A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for the simultaneous determination of a new potent motilin receptor agonist as erythromycin derivative, EM574 (erythromycin derivative), and its three metabolites, M-IV, M-V and M-VI, in human plasma was developed. The internal standards (I.S.s) used were deuterated EM574, M-IV and M-V. For the quantitation of M-VI, deuterated M-V was used. The analytes and I.S. were extracted from plasma samples with diethyl ether at neutral pH. A turbo ion spray interface was used as the ion source of LC-MS-MS, and the analysis was performed in the selected reaction monitoring mode. The lower quantitation limits for all the analytes were 0.05 ng/ml when 0.2 ml of plasma was used, and the standard curves were linear in the range 0.05 to 20 ng/ml. The method was precise; the intra- and inter-day precisions of the method were not more than 19.8% for all the analytes. The accuracy of the method was good with the deviations between added and calculated concentrations of each analyte being typically within +/- 11.2%.


Journal of Pharmaceutical and Biomedical Analysis | 2002

Highly sensitive liquid chromatography-tandem mass spectrometry method for quantification of a new bone anabolic agent, TAK-778, in human serum

Koichiro Teshima; Takahiro Kondo; Chie Maeda; Tsuneo Oda; Toshiaki Hagimoto; Ryoichi Tsukuda; Yoshinobu Yoshimura

A liquid chromatography-tandem mass spectrometric (LC-MS-MS) method for the highly sensitive determination of a new bone-anabolic agent, TAK-778 in human serum was developed. The internal standard (I.S.) used was deuterated TAK-778. TAK-778 and I.S. were extracted from serum samples with diethyl ether at neutral pH. A turbo ion spray interface was used as the ion source of LC-MS-MS, and the analysis was performed in the selected reaction monitoring mode. The lower limit of quantification was 0.02 ng/ml when 0.4 ml of serum was used, and the standard curve was linear in the range of 0.02-10 ng/ml. The method was precise; the intra- and inter-day precision of the method was not more than 17.9%. The accuracy of the method was good with the deviations between added and calculated concentration of TAK-778 being typically within 9.0%.


Journal of Chromatography B: Biomedical Sciences and Applications | 1995

Enantioselective determination of pazinaclone, a new isoindoline anxiolytic, and its active metabolite in rat plasma by high-performance liquid chromatography

Takahiro Kondo; Kenji Hamasaki; Masashi Yamaguchi; Isamu Aoki; Kiyoshi Yoshida; Yoshinobu Yoshimura; Shigeharu Tanayama

A sensitive and specific high-performance liquid chromatographic method has been developed for the simultaneous determination of the enantiomers of pazinaclone (DN-2327), a new anxiolytic agent, and those of its active metabolite, M-II, in rat plasma. Organic solvent extraction of pazinaclone, M-II, and internal standard (I.S.) in plasma was followed by separation of the analytes from other metabolites using an achiral reversed-phase column. Fluorescence detection was employed with excitation and emission wavelengths of 328 and 367 nm, respectively. Separation of all the enantiomers and I.S. was then accomplished with normal- and chiral-phase columns connected in series. For each analyte, the lower quantitation limit was 0.5 ng/ml. The assay has been applied to a chiral inversion study in rats. Chiral conversion from one enantiomer of pazinaclone to the other hardly occurred. This method is suitable for enantioselective pharmacokinetic and toxicokinetic studies in animals.


Journal of Chromatography B: Biomedical Sciences and Applications | 1998

Double column-switching high-performance liquid chromatographic method for the determination of TAK-603 and its metabolites in human serum

Toshiaki Hagimoto; Junya Okada; Michio Motohashi; Yoshinobu Yoshimura

A double column-switching high-performance liquid chromatographic (HPLC) method for the determination of concentrations for TAK-603 (T) and its metabolites, T-72258 (M-I) and T-72294 (M-III), in human serum was developed. The analytes were extracted with ethyl acetate from human serum samples treated with triethylamine and injected into the HPLC system. Separation of the analytes was performed on the HPLC system with double column-switching technique. The mobile phases A and B for the first column and the mobile phase C for the second column used were a mixture of methanol-10 mM aqueous ammonium acetate solution (1:1, v/v), methanol and a mixture of methanol-10 mM aqueous ammonium acetate solution (11:9, v/v), respectively. The eluate was monitored with a UV detector at a wavelength of 253 nm. The work-up procedure was reproducible and more than 90% of the analytes could be recovered from human serum. The lower limits of quantitation were all 1 ng/ml for the analytes when 0.5 ml of human serum was used. Standard curves were linear with a correlation coefficient (R) of more than 0.999 in the range of 1-500 ng/ml for T, M-I and M-III in human serum. The intra- and inter-day precision of the method for the various analytes were below 4.8%. The accuracy was good with the deviations between spiked and calculated concentrations of the analytes being within 11.0%. The method was successfully applied to analyze serum samples after an oral administration of T to healthy male volunteers.


Drug Research | 1997

Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys

Yoshihiro Maeshiba; Kiyota Y; Kenji Yamashita; Yoshinobu Yoshimura; Motohashi M; Tanayama S


Journal of Medicinal Chemistry | 1993

Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids

Keiji Kubo; Yasuhisa Kohara; Yoshinobu Yoshimura; Yoshiyuki Inada; Yumiko Shibouta; Yoshiyasu Furukawa; Takeshi Kato; Kohei Nishikawa; Takehiko Naka


Journal of Mass Spectrometry | 1996

Characterization of Conjugated Metabolites of a New Angiotensin II Receptor Antagonist, Candesartan Cilexetil, in Rats by Liquid Chromatography/Electrospray Tandem Mass Spectrometry Following Chemical Derivatization

Takahiro Kondo; Kiyoshi Yoshida; Yoshinobu Yoshimura; Michio Motohashi; Shigeharu Tanayama


The Journal of Antibiotics | 1992

Studies on condensed-heterocyclic azolium cephalosporins. IV. Synthesis and antibacterial activity of 7 beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- alkoxyiminoacetamido]-3-(condensed-heterocyclic azolium)methyl cephalosporins including SCE-2787.

Akio Miyake; Yoshinobu Yoshimura; Masayoshi Yamaoka; Tatsuo Nishimura; Naoto Hashimoto; Akira Imada

Collaboration


Dive into the Yoshinobu Yoshimura's collaboration.

Top Co-Authors

Avatar

Tatsuo Nishimura

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Akio Miyake

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takahiro Kondo

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsuo Numata

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Ryoichi Tsukuda

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takatsuka Yashiki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kenji Yamashita

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Naoto Hashimoto

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shigeharu Tanayama

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kunio Takanohashi

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge